viewABIOMED, Inc.

Abiomed surges as FDA approves blood pump device


Abiomed (NASDAQ:ABMD) surged in today’s trading after the provider of mechanical circulatory support devices said its miniature blood pump system that maintains heart function and circulation received approval from the U.S. Food and Drug Administration.

Shares soared 17 percent to $71.14 at 3:37 p.m. in Toronto. The stock has nearly tripled over the past six months.

The device, Impella 2.5 System, can be used during angioplasty and stenting, the regulator said.

Angioplasty and stenting are procedures used to re-open arteries in the heart that are blocked due to coronary artery disease, a condition that is the leading cause of death in the United States.

The FDA said data showed few later adverse events in patients using the pump during procedures, compared to those using the conventional intra-aortic balloon pump.

The Impella 2.5 System draws blood from the left lower chamber of the heart and pumps it to the main blood vessel to maintain stable heart function.

The device can be used in patients who have severe coronary artery disease but are not candidates for bypass treatment, the regulator said.

“The FDA approval of the Impella 2.5 device is one of our most significant milestones, representing a clinical advancement for physicians and patients,” the company’s chief executive officer Michael Minogue said in a statement. “The FDA's recognition of this elective and urgent patient population is an important acknowledgement of their growing need for treatment.”

Quick facts: ABIOMED, Inc.

Price: 150.26 USD

Market: NASDAQ
Market Cap: $6.77 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: MariMed seeing strong sales numbers with Cannabis infused...

MariMed (OTCQB: MRMD) CEO Bob Fireman and SVP of sales Ryan Crandall joined Steve Darling from Proactive to discuss the company’s new cannabis-infused hot sauce. That sauce becomes the first cannabis product produced in Puerto Rico and sold in the U.S. Crandall telling Proactive the story behind...

2 hours, 39 minutes ago

2 min read